oncology
Cancer care

Female oncology patients’ fertility testing rejected by Medicare


Medicare has knocked back a bid to give female oncology patients access to a test of ovarian reserve that would help decision making on fertility preservation when undergoing gonadotoxic chemotherapy. An application by clinicians for an MBS item for Anti-Mullerian hormone (AMH) testing in premenopausal female cancer patients was rejected by the Medicare Services Advisory ...

Already a member?

Enter your email to keep reading.


OR